Nothing Special   »   [go: up one dir, main page]

AR110526A1 - Anticuerpos anti-ox40 y sus usos en el tratamiento del cáncer - Google Patents

Anticuerpos anti-ox40 y sus usos en el tratamiento del cáncer

Info

Publication number
AR110526A1
AR110526A1 ARP170103527A ARP170103527A AR110526A1 AR 110526 A1 AR110526 A1 AR 110526A1 AR P170103527 A ARP170103527 A AR P170103527A AR P170103527 A ARP170103527 A AR P170103527A AR 110526 A1 AR110526 A1 AR 110526A1
Authority
AR
Argentina
Prior art keywords
antibodies
cancer treatment
seq
amino acid
acid sequence
Prior art date
Application number
ARP170103527A
Other languages
English (en)
Inventor
Fiona A Harding
Original Assignee
Abbvie Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Biotherapeutics Inc filed Critical Abbvie Biotherapeutics Inc
Publication of AR110526A1 publication Critical patent/AR110526A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proveen anticuerpos anti-OX40, composiciones que los comprenden, ácidos nucleicos que los codifican y métodos para prepararlos y usarlos. Reivindicación 1: Un anticuerpo anti-OX40 caracterizado porque comprende una cadena pesada que tiene una secuencia de aminoácidos según SEQ ID Nº 41 ó 42 y una cadena liviana que tiene una secuencia de aminoácidos según SEQ ID Nº 51.
ARP170103527A 2016-12-15 2017-12-15 Anticuerpos anti-ox40 y sus usos en el tratamiento del cáncer AR110526A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662434761P 2016-12-15 2016-12-15

Publications (1)

Publication Number Publication Date
AR110526A1 true AR110526A1 (es) 2019-04-10

Family

ID=60937946

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170103527A AR110526A1 (es) 2016-12-15 2017-12-15 Anticuerpos anti-ox40 y sus usos en el tratamiento del cáncer

Country Status (37)

Country Link
US (7) US10556962B2 (es)
EP (2) EP3725809A1 (es)
JP (2) JP6772385B2 (es)
KR (2) KR20210157471A (es)
CN (1) CN110573527A (es)
AR (1) AR110526A1 (es)
AU (1) AU2017377036B2 (es)
BR (2) BR112019012328A2 (es)
CA (1) CA3045940A1 (es)
CL (1) CL2019001646A1 (es)
CO (1) CO2019007288A2 (es)
CR (1) CR20190330A (es)
CY (1) CY1123274T1 (es)
DK (1) DK3504242T3 (es)
DO (1) DOP2019000165A (es)
EC (1) ECSP19050049A (es)
ES (1) ES2813057T3 (es)
HR (1) HRP20201259T1 (es)
HU (1) HUE050399T2 (es)
IL (1) IL267070A (es)
LT (1) LT3504242T (es)
MA (1) MA53184A (es)
MX (1) MX2019007121A (es)
MY (1) MY198059A (es)
PE (1) PE20191403A1 (es)
PH (1) PH12019501357A1 (es)
PL (1) PL3504242T3 (es)
PT (1) PT3504242T (es)
RS (1) RS60664B1 (es)
RU (1) RU2753493C2 (es)
SG (1) SG10201914126RA (es)
SI (1) SI3504242T1 (es)
SM (1) SMT202000462T1 (es)
TW (1) TWI734879B (es)
UA (1) UA125041C2 (es)
UY (1) UY37523A (es)
WO (1) WO2018112346A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE050399T2 (hu) * 2016-12-15 2020-12-28 Abbvie Biotherapeutics Inc Anti-OX40 antitestek és alkalmazásuk
US20200181275A1 (en) * 2017-06-09 2020-06-11 Glaxosmithkline Intellectual Property Development Limited Combination therapy with icos agonist and ox40 agonist to treat cancer
WO2019028182A2 (en) * 2017-08-01 2019-02-07 Remd Biotherapeutics, Inc. TREATMENT OF CANCER USING ANTIBODIES BINDING TO THE HUMAN CD134 RECEPTOR (OX40)
CN110790837A (zh) * 2018-08-02 2020-02-14 上海君实生物医药科技股份有限公司 抗btla抗体
WO2020119789A1 (en) * 2018-12-14 2020-06-18 Wuxi Biologics (Shanghai) Co., Ltd. Fully human antibodies against ox40, method for preparing the same, and use thereof
US12195545B2 (en) 2018-12-25 2025-01-14 Hanx Biopharmaceutics, Inc Anti-OX40 monoclonal antibody and application thereof
CN110172090B (zh) * 2019-06-03 2020-04-03 中山标佳生物科技有限公司 Cd134单克隆抗体及其制备方法和癌症治疗中的应用
WO2021098851A1 (en) * 2019-11-20 2021-05-27 Eucure (Beijing) Biopharma Co., Ltd Anti-ctla4/ox40 bispecific antibodies and uses thereof
WO2021127262A1 (en) 2019-12-17 2021-06-24 Amgen Inc. Dual interleukin-2 /tnf receptor agonist for use in therapy
CN113045654A (zh) * 2019-12-27 2021-06-29 南开大学 抗ox40抗体及其用途
CN111303285B (zh) * 2019-12-27 2023-06-02 百力司康生物医药(杭州)有限公司 靶向ox40的抗体及其制备方法和应用
WO2021190431A1 (zh) * 2020-03-23 2021-09-30 百奥泰生物制药股份有限公司 一种免疫细胞激活剂的开发及应用
US20230295324A1 (en) * 2020-06-30 2023-09-21 Harbour Biomed (Shanghai) Co., Ltd Ox40-targeted antibody, and preparation method therefor and application thereof
CN111704671B (zh) * 2020-08-19 2020-11-24 广东赛尔生物科技有限公司 Ox40抗体及其在治疗癌症中的应用
CN112442121A (zh) * 2020-08-20 2021-03-05 山东兴瑞生物科技有限公司 Ox40抗体、其编码基因、及抗体的制备方法和在增强人体免疫功能中的应用
CN114106173A (zh) * 2020-08-26 2022-03-01 上海泰槿生物技术有限公司 抗ox40抗体、其药物组合物及应用
CN111763258B (zh) * 2020-09-01 2020-12-29 北京百奥赛图基因生物技术有限公司 抗ox40抗体及其用途
CN114515335A (zh) * 2020-11-19 2022-05-20 百奥泰生物制药股份有限公司 抗ox40抗体在治疗肿瘤或癌症中的应用
EP4255929A2 (en) 2020-12-02 2023-10-11 Vib Vzw An ltbr agonist in combination therapy against cancer
CN115260312B (zh) * 2021-04-30 2025-02-14 保诺科技（北京）有限公司 结合ox40的抗体或抗原结合片段

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
KR100654645B1 (ko) 1995-04-27 2007-04-04 아브게닉스, 인크. 면역화된 제노마우스 유래의 인간 항체
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
DK0970126T3 (da) 1997-04-14 2001-08-13 Micromet Ag Hidtil ukendt fremgangsmåde til fremstillingen af anti-humant antigen-receptorer og anvendelser deraf
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
AU2873999A (en) 1998-02-24 1999-09-06 Sisters Of Providence In Oregon Compositions containing an OX-40 receptor binding agent or nucleic acid encoding the same and methods for enhancing antigen-specific immune response
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
AU2003257419B2 (en) 2002-06-13 2010-02-25 Crucell Holland, B.V. OX40 (CD134) receptor agonistic and therapeutic use
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
CA2587766A1 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
WO2007084559A2 (en) 2006-01-13 2007-07-26 Board Of Regents, The University Of Texas System Methods to treat disease states by influencing the signaling of ox40-receptors and high throughput screening methods for identifying substances therefor
MX2010006466A (es) 2007-12-14 2010-09-28 Bristol Myers Squibb Co Moleculas de union al receptor ox40 de humano.
EA029793B1 (ru) * 2010-08-23 2018-05-31 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Антитела к ох40 и способы их применения
KR101685262B1 (ko) * 2011-08-23 2016-12-21 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항-ｏｘ４０ 항체 및 이의 사용 방법
CA2904528C (en) 2013-03-15 2021-01-19 Abbvie Biotherapeutics Inc. Fc variants
CA2907436A1 (en) * 2013-03-18 2014-09-25 Biocerox Products B.V. Humanized anti-cd134 (ox40) antibodies and uses thereof
MX2016012779A (es) 2014-03-31 2017-04-27 Genentech Inc Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
TW201619200A (zh) 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
US20160160290A1 (en) * 2014-11-03 2016-06-09 Genentech, Inc. Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
MA42043A (fr) * 2015-05-07 2018-03-14 Agenus Inc Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
EP3298045A1 (en) * 2015-05-21 2018-03-28 Alligator Bioscience AB Novel polypeptides
US20160347848A1 (en) * 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
MA43389A (fr) 2015-12-02 2021-05-12 Agenus Inc Anticorps anti-ox40 et leurs procédés d'utilisation
HUE050399T2 (hu) * 2016-12-15 2020-12-28 Abbvie Biotherapeutics Inc Anti-OX40 antitestek és alkalmazásuk

Also Published As

Publication number Publication date
ES2813057T3 (es) 2021-03-22
CN110573527A (zh) 2019-12-13
JP2021019603A (ja) 2021-02-18
RU2753493C2 (ru) 2021-08-17
US20200048363A1 (en) 2020-02-13
KR102341926B1 (ko) 2021-12-23
IL267070A (en) 2019-08-29
US20180171023A1 (en) 2018-06-21
HUE050399T2 (hu) 2020-12-28
US10040864B2 (en) 2018-08-07
EP3725809A1 (en) 2020-10-21
US20180346593A1 (en) 2018-12-06
US20200181282A1 (en) 2020-06-11
AU2017377036A1 (en) 2019-07-11
EP3504242A1 (en) 2019-07-03
SI3504242T1 (sl) 2020-10-30
PT3504242T (pt) 2020-08-26
CL2019001646A1 (es) 2019-08-23
HRP20201259T1 (hr) 2020-11-13
RS60664B1 (sr) 2020-09-30
MX2019007121A (es) 2020-02-05
SG10201914126RA (en) 2020-02-27
TW201825520A (zh) 2018-07-16
KR20210157471A (ko) 2021-12-28
DOP2019000165A (es) 2019-07-15
RU2019121895A3 (es) 2021-02-15
EP3504242B1 (en) 2020-06-24
US20210017289A1 (en) 2021-01-21
JP6772385B2 (ja) 2020-10-21
MA53184A (fr) 2021-05-26
CY1123274T1 (el) 2021-12-31
US10604584B2 (en) 2020-03-31
US20180194855A1 (en) 2018-07-12
UY37523A (es) 2018-07-31
AU2017377036B2 (en) 2022-06-23
ECSP19050049A (es) 2019-07-31
BR112019012328A2 (pt) 2019-11-19
PL3504242T3 (pl) 2020-11-16
US20220112304A1 (en) 2022-04-14
CR20190330A (es) 2019-12-19
BR122020025629B1 (pt) 2022-05-31
PH12019501357A1 (en) 2020-01-20
SMT202000462T1 (it) 2020-09-10
KR20190092552A (ko) 2019-08-07
UA125041C2 (uk) 2021-12-29
TWI734879B (zh) 2021-08-01
JP2020504101A (ja) 2020-02-06
DK3504242T3 (da) 2020-08-17
LT3504242T (lt) 2020-09-10
MY198059A (en) 2023-07-31
RU2019121895A (ru) 2021-01-15
US10556962B2 (en) 2020-02-11
CA3045940A1 (en) 2018-06-21
CO2019007288A2 (es) 2019-08-20
PE20191403A1 (es) 2019-10-04
WO2018112346A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
AR110526A1 (es) Anticuerpos anti-ox40 y sus usos en el tratamiento del cáncer
CY1123932T1 (el) Δομες πολυειδικου αντισωματος
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
CY1123642T1 (el) Αντισωματα enanti-pd-1
CY1124806T1 (el) Αντισωματα enanti-cd40 και χρησεις αυτων
CY1122721T1 (el) Αντισωματα που δεσμευουν αχl
ECSP19011185A (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a CD3 y CD123
CL2017002728A1 (es) Método para el tratamiento de cáncer
DOP2018000259A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
PE20190108A1 (es) Moleculas de anticuerpo para el tratamiento del cancer
CO2017010502A2 (es) Receptores del antígeno quimérico dirigidos al antígeno de maduración de células b
CL2017000954A1 (es) Moléculas de unión a antígeno biespecificas activadoras de células t
BR112019011450A2 (pt) células naturais killer modificadas e uso das mesmas
AR102879A1 (es) Métodos para el tratamiento de tumores cerebrales
MX2022016002A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
CO6761352A2 (es) Anticuerpos neutralizadores anti-ccl20
PE20181076A1 (es) Nuevos moduladores y metodos para su uso
UY35444A (es) Anticuerpos anti-tnf alfa mutados y métodos para su utilización
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
PE20190209A1 (es) Anticuerpos anti-factor bb del complemento y uso de estos
MX2023001540A (es) Vacunas contra el cancer y metodos de tratamiento que las utilizan.
CY1120997T1 (el) Πρωτεϊνες συντηξης uti
CY1122728T1 (el) Αντισωματα εναντι hpa-1a
CO2020005371A2 (es) Anticuerpos anti-apoc3 y métodos de uso de estos
PE20180498A1 (es) Inmunoglobulinas conjugadas en cys80

Legal Events

Date Code Title Description
FB Suspension of granting procedure